LakeShore Biopharma

LakeShore Biopharma

LakeShore Biopharma was formed in 2021 through the merger of Yisheng Bio, a Chinese pharmaceutical manufacturer with a marketed rabies vaccine, and a US-domiciled clinical-stage biotech. The combined entity began trading on Nasdaq in March 2023 after closing a business combination with Vantage Merger Corp., a special-purpose acquisition company. The firm's operational history, however, traces to 2010, when YishengBio first received Chinese regulatory approval for its vero-cell rabies vaccine. The company's revenue engine is its biologics business in China. YishengBio's freeze-dried human rabies vaccine, marketed as Yisheng Pika, has been distributed in China since 2003 and accounted for essentially all recognized revenue through the de-SPAC close. LakeShore deploys those revenues across two parallel pipelines: a next-generation freeze-dried rabies vaccine for the Chinese market and an immune-oncology program in the US led by YS-ON-001, an injectable biologic targeting liver, breast, and pancreatic cancers. The pipeline also includes YS-HBV-001, a therapeutic hepatitis B vaccine, and YS-HBV-002, targeting chronic hepatitis B in combination with nucleotide analogs. The firm's geographic footprint concentrates lab and clinical operations in Beijing for manufacturing and Gaithersburg, Maryland for US-based R&D. As of its 2023 market debut, LakeShore had generated approximately $40 million in annual vaccine revenue from its China operations, though no updated deployment or headcount figures have been published. The firm operates auxiliary clinical development sites in Singapore and maintains a wholly-owned Chinese manufacturing subsidiary that handles production, cold-chain logistics, and regulatory affairs for the existing vaccine franchise. June 2023: The company opened a new US research facility in Gaithersburg focused on immuno-oncology asset development. What structurally differentiates LakeShore is the revenue-funded biotech model applied across two sovereign regulatory regimes. Instead of relying solely on dilutive US venture rounds, the firm uses Chinese biologic sales to underwrite Phase I/II oncology trials run through US clinical sites — a reverse-subsidy architecture rarely seen among China-cross US-listed biotechs. The SPAC sponsor, Vantage, retained a board presence post-close, and principal shareholder structures remain concentrated among former YishengBio insiders and de-SPAC institutional participants.